International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 : 1000-1002
Original Article
Effect of Adding Dexmedetomidine versus Fentanyl to Intrathecal Levobupivacaine 0.5% on Spinal Block in LSCS
Published
June 18, 2023
Abstract

Background: Spinal anaesthesia is the preferred technique for lower segment caesarean section (LSCS) due to rapid onset, dense sensory block, and minimal drug exposure to the fetus. Adjuvants such as dexmedetomidine and fentanyl are commonly added to intratheral local anesthetics to enhance the quality and duration of block.

Aim: To compare the efficacy and safety of adding dexmedetomidine versus fentanyl to intrathecal levobupivacaine 0.5% in parturients undergoing LSCS.

Methods: In this prospective, randomized, double-blind study, 50 ASA II parturients were randomly allocated into two groups (n=25 each). Group D received 2.5 ml of 0.5% levobupivacaine with dexmedetomidine 5 μg, while Group F received 2.5 ml of 0.5% levobupivacaine with fentanyl 25 μg. Onset time, duration of sensory and motor block, hemodynamic parameters, and adverse effects were recorded.

Results: Group D showed significantly faster onset of sensory block (2.3±0.5 min) compared to Group F (3.1±0.6 min, p<0.001) and longer duration of sensory block (262±18 min vs. 218±20 min, p<0.001). Duration of motor block was also prolonged in Group D (210±15 min) compared to Group F (175±14 min, p<0.001). Hemodynamic stability was comparable in both groups, with mild bradycardia observed in 2 patients in Group D and pruritus in 4 patients in Group F.

Conclusion: Intrathecal dexmedetomidine with levobupivacaine provides earlier onset and longer duration of sensory and motor block compared to fentanyl, with comparable safety in LSCS.

Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
1127 Views
101 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved